Loading…
Halozyme Therapeutics, Inc. is projected to rise to $90.46 by 2027, a +19% move from its current price of $76.20. HALO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $74.90 | $76.22 | $77.56 | +0.03% |
| Jul 14 | $74.38 | $76.24 | $78.14 | +0.05% |
| Jul 15 | $73.99 | $76.26 | $78.60 | +0.08% |
| Jul 16 | $73.67 | $76.28 | $78.98 | +0.10% |
| Jul 17 | $73.38 | $76.30 | $79.33 | +0.13% |
| Jul 18 | $73.13 | $76.32 | $79.65 | +0.15% |
| Jul 19 | $72.90 | $76.34 | $79.94 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $72.90 | $76.34 | $79.94 | +0.18% |
| Week 2 | $71.65 | $76.48 | $81.63 | +0.36% |
| Week 3 | $70.73 | $76.61 | $82.98 | +0.54% |
| Week 4 | $69.99 | $76.75 | $84.16 | +0.72% |
| Week 5 | $69.36 | $76.89 | $85.24 | +0.90% |
| Week 6 | $68.80 | $77.03 | $86.24 | +1.09% |
| Week 7 | $68.31 | $77.17 | $87.18 | +1.27% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Halozyme Therapeutics, Inc. is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. Its products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Halozyme offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy.
The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc.
The company was founded in 1998 and is headquartered in San Diego, California.
Halozyme Therapeutics, Inc. (HALO) is a healthcare company with a current price of $80.78 and a market capitalization of $9.58B, ranking 949. It trades within a 30-day range of $72.20 to $90.38, with near-term support at $66.28 and resistance at $80.78.
The technical picture is bullish, supported by RSI(14) at 70 and moving averages above the current level (SMA50 at $69.27 and SMA200 at $69.13). The 30-day volatility is high at 30%. The long-run forecast shows a bullish trajectory, with the average price climbing from $80.78 in 2026 toward higher levels by 2030, 2040, and 2050, accompanied by sizable returns implied by the projected ROIs.
A major floor 22.1% below — a decisive break under it would weaken the trend.
The nearest floor, 13.0% below — buyers have tended to step in here.
The nearest ceiling, 7.0% above — a clean break opens room to run.
A major ceiling 18.1% above — clearing it would confirm fresh momentum.
Key HALO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HALO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $79.51 | Sell | $78.30 | Sell |
| MA 10 | $78.44 | Sell | $77.54 | Sell |
| MA 20 | $74.25 | Buy | $75.37 | Buy |
| MA 50 | $70.39 | Buy | $71.96 | Buy |
| MA 100 | $68.62 | Buy | $70.19 | Buy |
| MA 200 | $69.17 | Buy | $68.34 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.50 | Neutral |
| Stoch RSI (14) | 21.77 | Neutral |
| CCI (20) | 30.98 | Neutral |
| Williams %R (14) | -42.69 | Info |
| MACD (12,26,9) | 0.26 | Buy |
| ROC (12) | 9.45 | Buy |
| Bollinger %B (20,2) | 0.61 | Neutral |
| Stochastic %K (14) | 57.31 | Neutral |
| TRIX (15) | 0.49 | Buy |
| Awesome (5,34) | 7.33 | Buy |
| Ultimate (7,14,28) | 51.74 | Neutral |
| Momentum (10) | 3.56 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 79.31 | Sell |
| ADX (14) | 24.56 | Buy |
| ATR (14) | 1.38 | Info |
The 30-day technical picture is bullish, with RSI(14) at 70, suggesting strong momentum. The stock trades above both the SMA50 ($69.27) and the SMA200 ($69.13), indicating constructive near-term momentum.
Near-term levels show a defined trading range, with support at $66.28 and resistance at $80.78. The 30-day price range spans from $72.20 to $90.38, highlighting ongoing volatility within a bullish context.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $61.63 | $76.20 | $97.00 | 0% | Neutral | |
| $74.09 | $90.46 | $115.48 | +19% | Neutral | |
| $84.90 | $105.60 | $138.45 | +39% | Bullish | |
| $97.21 | $122.78 | $164.40 | +61% | Bullish | |
| $119.47 | $152.94 | $208.47 | +101% | Bullish | |
| $132.96 | $172.30 | $238.57 | +126% | Bullish | |
| $140.01 | $183.48 | $257.67 | +141% | Bullish | |
| $154.65 | $204.80 | $291.33 | +169% | Bullish | |
| $157.40 | $210.52 | $303.05 | +176% | Bullish | |
| $179.41 | $242.21 | $352.56 | +218% | Bullish | |
| $260.57 | $366.91 | $559.67 | +382% | Bullish | |
| $547.09 | $826.23 | $1,350.96 | +984% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $61.63 | $76.20 | $89.78 | +0.00% |
| August 2026 | $64.86 | $75.92 | $90.78 | -0.37% |
| September 2026 | $66.33 | $78.01 | $94.01 | +2.76% |
| October 2026 | $66.87 | $78.97 | $95.80 | +1.23% |
| November 2026 | $65.79 | $77.97 | $95.11 | -1.27% |
| December 2026 | $66.54 | $79.12 | $97.00 | +1.47% |
Click any year to see its month-by-month HALO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, HALO is projected to trade between $61.63 and $97.00, averaging $76.20 — a potential gain of 0% from today's $76.20. A consolidation phase looks the most probable path here.
Halozyme Therapeutics, Inc.'s 2027 outlook centres on $90.46, within a $74.09 to $115.48 range. That is up +19% on the projected 2026 average. That marks a +19% change versus current levels. Price action looks broadly range-bound.
By 2028, HALO could reach as high as $138.45, with a base case around $105.60 and support toward $84.90 — roughly +39% from $76.20. Buyers look set to stay in control over this stretch.
Expect HALO to range from $97.21 to $164.40 through 2029. The $122.78 average target implies a +61% move from current prices. That is up +16% on the projected 2028 average. Momentum favours further upside here.
The HALO price prediction for 2030 points to an average of $152.94 (low $119.47, high $208.47) — a potential gain of +101% on today's $76.20. Buyers look set to stay in control over this stretch.
In 2031, HALO is projected to trade between $132.96 and $238.57, averaging $172.30 — a potential gain of +126% from today's $76.20. That is up +13% on the projected 2030 average. Momentum favours further upside here.
Halozyme Therapeutics, Inc.'s 2032 outlook centres on $183.48, within a $140.01 to $257.67 range. That is up +6% on the projected 2031 average. That marks a +141% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, HALO could reach as high as $291.33, with a base case around $204.80 and support toward $154.65 — roughly +169% from $76.20. Momentum favours further upside here.
Expect HALO to range from $157.40 to $303.05 through 2034. The $210.52 average target implies a +176% move from current prices. That is up +3% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The HALO price prediction for 2035 points to an average of $242.21 (low $179.41, high $352.56) — a potential gain of +218% on today's $76.20. Momentum favours further upside here.
In 2040, HALO is projected to trade between $260.57 and $559.67, averaging $366.91 — a potential gain of +382% from today's $76.20. That is up +51% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Halozyme Therapeutics, Inc.'s 2050 outlook centres on $826.23, within a $547.09 to $1,350.96 range. That is up +125% on the projected 2040 average. That marks a +984% change versus current levels. Momentum favours further upside here.
Investing $1,000 in HALO today (≈ 13.12336 HALO) could be worth
$10,842.97
+$9,842.97 (+984%) by 2050 · US Dollar
Based on the average projected HALO price of $826.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HALOwould be worth at today's price.
$1,000 invested in HALO on Jul 10, 2025 (≈ 17.352073 HALO) would be worth
$1,322.23
+$322.23 (+32.2%) today · 1.32× · US Dollar
Based on a HALO entry price of $57.63 vs. today's $76.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $79.45 | $959.09 | -4.1% |
| 1 month ago | $70.5 | $1,080.85 | +8.1% |
| 3 months ago | $67.82 | $1,123.56 | +12.4% |
| 6 months ago | $72.42 | $1,052.2 | +5.2% |
| 1 year ago | $57.63 | $1,322.23 | +32.2% |
| All time (5.0y) ago | $44.9 | $1,697.1 | +69.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HALO forecast.
Our base-case forecast reaches $150.00 around 2030.
Implied market cap at $150.00: $17.79B
The multi-year forecast paints a bullish stance across the horizon. In 2026 the min price is $61.63, the avg is $80.78, and the max is $104.24, with ROI of 0 and sentiment labeled as Neutral. By 2027, the min is $80.27, the avg is $98.04, the max is $125.20, and ROI is 21.4 with a bullish signal.
By 2030 the min is $133.89, the avg is $171.44, the max is $233.74, with ROI of 112.2 and bullish sentiment. The forecast continues to 2040 with an avg of $434.09, a max of $662.22 and ROI of 437.4, and reaches 2050 with an avg of $1,002.11, a max of $1,638.66 and ROI of 1140.5, all labeled bullish.
These figures represent estimates of future pricing and are not guarantees. The projected path shows substantial upside potential over the long term, but actual results may differ.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $171.44, a min of $133.89, and a max of $233.74, with an ROI of 112.2% and bullish sentiment.
The forecast indicates bullish sentiment in later years with rising averages and high ROIs (e.g., 112.2% by 2030 and 1140.5% by 2050), but these are estimates and not guarantees.
Yes. The forecast max in 2030 is $233.74, which exceeds $200, and subsequent years show higher max values (e.g., 2031 $269.12, 2032 $294.23, 2033 $332.79).
For 2026, the min is $61.63, the avg is $80.78, the max is $104.24, and the sentiment is Neutral.
Current price is $80.78 and market cap is $9.58B.
Halozyme Therapeutics, Inc. Community Discussion
0Share your Halozyme Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.